Saxenda Side Effects: Severity Distribution by Patient Phenotype

Print or save as PDF

Does the Saxenda label sort side effects into mild, moderate or severe?

No. The label reports the percentage of trial patients who had each reaction and lists serious reactions separately, with no mild-to-severe distribution [1]. The adult figures come from five placebo-controlled trials, 3,384 on Saxenda vs 1,941 on placebo, treated up to 56 weeks at 3 mg daily [1]. Nausea led at 39.3% vs 13.8%, then diarrhea 20.9% vs 9.9%, constipation 19.4% vs 8.5% and vomiting 15.7% vs 3.9% [1]. The label notes that nausea declined as treatment continued, and it describes the weekly step-up from 0.6 mg to 3 mg as a way to reduce the risk of gastrointestinal reactions [1].

Which patients get their own side-effect numbers?

The label has separate adverse-reaction tables for adults and for adolescents aged 12 to 17 [1]. It also reports hypoglycemia results for adults with type 2 diabetes, including those taking a sulfonylurea [1].

Adults with type 2 diabetes

In Study 2 (423 on Saxenda, 212 on placebo), blood glucose below 54 mg/dL in patients not taking insulin occurred in 12.6% vs 6.6% [1]. Among patients taking a sulfonylurea, whose doses were cut 50% at the start of the trial, the rate was 28.2% vs 12.7%; among those not taking one, 7.1% vs 4.5% [1]. Severe hypoglycemia requiring another person's help occurred in 3 of 422 Saxenda patients (0.7%), all taking a sulfonylurea, and none of 212 placebo patients [1].

Adolescents aged 12 to 17

The 56-week pediatric trial (125 on Saxenda, 126 on placebo) reported nausea 42.4% vs 14.3%, vomiting 34.4% vs 4%, diarrhea 22.4% vs 14.3% and symptomatic hypoglycemia below 70 mg/dL in 15.2% vs 4% [1]. None of these adolescents had type 2 diabetes; blood glucose below 54 mg/dL occurred in 1.6% vs 0.8% [1]. Stopping treatment for adverse reactions was 10.4% vs 0% [1]. The label allows pediatric titration to take up to 8 weeks and a reduction to 2.4 mg daily if 3 mg is not tolerated [1].

Which conditions does the label flag for extra caution?

The label says Saxenda is not recommended in patients with severe gastroparesis [1]. It says to monitor heart rate at regular intervals, and to monitor renal function in patients reporting adverse reactions that could lead to volume depletion [1].

What serious reactions does the label list?

The label lists acute pancreatitis, including fatal and non-fatal cases, as a reaction seen with GLP-1 receptor agonists including liraglutide, and says to discontinue Saxenda if pancreatitis is suspected [1]. Cholelithiasis occurred in 2.2% of Saxenda-treated patients versus 0.8% of placebo-treated patients, and cholecystitis occurred in 0.8% versus 0.4%; the label states that the majority of Saxenda-treated patients with these adverse events required cholecystectomy [1]. A resting heart-rate rise of more than 10 bpm at two consecutive visits occurred in 34% vs 19% [1]. The boxed warning covers thyroid C-cell tumors, which liraglutide caused in rats and mice at clinically relevant exposures; human relevance is unknown, and a personal or family history of medullary thyroid carcinoma or MEN 2 is a contraindication [1]. The suicidal behavior and ideation warning in the 2024 Saxenda label is absent from the current label; FDA requested its removal on 2026-01-13 after a review that found no increased risk [2][3][1].